Benchmark Reiterates Speculative Buy Rating for Reviva Pharmaceuticals (NASDAQ:RVPH)

Reviva Pharmaceuticals (NASDAQ:RVPH)‘s stock had its “speculative buy” rating reaffirmed by equities researchers at Benchmark in a research note issued on Tuesday, Benzinga reports. They currently have a $17.00 price target on the stock. Benchmark’s price target would suggest a potential upside of 431.25% from the company’s current price.

Separately, HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of Reviva Pharmaceuticals in a research report on Monday, March 25th.

Reviva Pharmaceuticals Price Performance

Shares of RVPH opened at $3.20 on Tuesday. The firm has a 50-day moving average of $3.71 and a 200-day moving average of $4.18. The company has a market cap of $89.34 million, a PE ratio of -1.95 and a beta of -0.02. Reviva Pharmaceuticals has a one year low of $2.67 and a one year high of $9.25.

Hedge Funds Weigh In On Reviva Pharmaceuticals

Several large investors have recently modified their holdings of RVPH. Armistice Capital LLC boosted its holdings in shares of Reviva Pharmaceuticals by 194.0% during the 4th quarter. Armistice Capital LLC now owns 1,764,000 shares of the company’s stock worth $9,085,000 after buying an additional 1,164,000 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Reviva Pharmaceuticals by 58.3% during the fourth quarter. Vanguard Group Inc. now owns 974,982 shares of the company’s stock worth $5,021,000 after acquiring an additional 359,050 shares during the period. Colony Group LLC grew its position in shares of Reviva Pharmaceuticals by 66.7% in the second quarter. Colony Group LLC now owns 155,000 shares of the company’s stock valued at $908,000 after purchasing an additional 62,000 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Reviva Pharmaceuticals by 3.8% in the second quarter. Geode Capital Management LLC now owns 150,949 shares of the company’s stock valued at $885,000 after purchasing an additional 5,519 shares during the last quarter. Finally, EMC Capital Management increased its stake in shares of Reviva Pharmaceuticals by 1,294.3% during the third quarter. EMC Capital Management now owns 123,915 shares of the company’s stock worth $613,000 after purchasing an additional 115,028 shares during the period. 63.18% of the stock is owned by institutional investors.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for use in the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis.